GlaxoSmithKline does better in Q3


GlaxoSmithKline did better than it expected in the third quarter, showing increases in sales and revenue, despite a drop in net profit. 

While profit was down $2.1 billion compared to a year ago, revenue was up 7 percent to $9.6 billion. Per share earnings also went up 6 percent to 41 cents a share.

GSK CEO, Andrew Witty (photo), attributes the positive results to the "considerable transition" occurring in its portfolio, but fluctuation of the British Pound also appeared to play a role. Stronger Advair sales helped during the quarter, as well.   

The company has held on fairly well in these tough economic times, but is expecting sales to drop for some of its key products, including Avandia for diabetes, the depression med Wellbutrin and its heart medication, Coreg. Avandia is likely to suffer most, due to a newer FDA black box label warning. 

The company will be exploring small-to-medium acquisition opportunities, as well as opportunities to diversify, moving forward. 

- read the Wall Street Journal article 


Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.